Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 11Gastrointestinal 2Other hematologic neoplasm 1CNS 1

Conditions

Brain Neoplasms 133Glioblastoma 92Astrocytoma 44Neuroblastoma 40Glioma 40Central Nervous System Neoplasms 38Neoplasms 26Breast Neoplasms 25Neoplasm Metastasis 24Oligodendroglioma 20Gliosarcoma 19Carcinoma, Non-Small-Cell Lung 18Lymphoma, Follicular 14Recurrence 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Medulloblastoma 13Burkitt Lymphoma 13Testicular Neoplasms 12Lymphoma, T-Cell, Cutaneous 12Lymphoma, Non-Hodgkin 12Lymphoma, Mantle-Cell 12Lymphoma, Large-Cell, Immunoblastic 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma, B-Cell, Marginal Zone 12Leukemia, Lymphocytic, Chronic, B-Cell 12Hodgkin Disease 12Sezary Syndrome 11Primary Myelofibrosis 11Mycosis Fungoides 11Leukemia, Myeloid, Chronic-Phase 11

Interventions

Dalteparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pulmonary Embolism × CNS × Clear all
NCT00135876 2007-04-27

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

Ontario Clinical Oncology Group (OCOG)

Phase 3 Completed
512 enrolled
CNSClassical hematology

Brain Neoplasms, Glioma, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡